Funded Biotechnology Startups in Watertown
Among the 19 Watertown, Massachusetts biotechnology rounds shown, the largest disclosed amount is Affini-T Therapeutics’ $175M dated 2022-03-22.
Among the 19 Watertown, Massachusetts biotechnology rounds shown, the largest disclosed amount is Affini-T Therapeutics’ $175M dated 2022-03-22. That figure dwarfs the rest of the disclosed entries, with the next-largest amounts clustering lower at $130M (Syros Pharmaceuticals, 2022-07-05) and $125M (Diagonal Therapeutics, 2026-01-08), while multiple rounds sit in the $100M–$125M band (e.g., Lyndra Therapeutics $101M on 2023-12-21; Neumora Therapeutics $112M on 2022-10-11). Smaller disclosed rounds range down to $1M for Dynamic Cell Therapies (2024-07-11) and $2M for SQZ Biotech (2022-03-21), with one additional record showing an undisclosed amount for Fluent BioSciences (2024-03-21). Date-wise, the list is front-loaded at the high end: 2026 accounts for the two most recent entries (Portal $9M on 2026-06-18; Entact Bio $10M on 2026-06-03) and the earliest round shown is 2022-03-09 (EyePoint Pharmaceuticals, $45M), spanning roughly 3+ years. Staging is dispersed—five of the 19 entries are labeled “Series Unknown” ($10M on 2026-06-03; $10M on 2025-02-19; $1M on 2024-07-11; $5M on 2024-06-21; $60M on 2023-11-13)—and the only “undisclosed” amount appears once (Fluent BioSciences, 2024-03-21).
Most recent rounds
19 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Watertown biotech set, and how does it compare to the next-largest disclosed amounts?
Affini-T Therapeutics’ $175M round dated 2022-03-22 is the clear top disclosed figure. The next-largest disclosed amounts are $130M (Syros Pharmaceuticals, 2022-07-05) and $125M (Diagonal Therapeutics, 2026-01-08), meaning the largest disclosed round sits well above the rest of the disclosed range.
Are there any major low-end outliers among the disclosed amounts (excluding “undisclosed”)?
Yes: Dynamic Cell Therapies posted a disclosed $1M on 2024-07-11, which is far below other small disclosed rounds like SQZ Biotech’s $2M (2022-03-21) and the $5M for Ingenia Therapeutics (2024-06-21). Fluent BioSciences is the one entry marked “undisclosed” (2024-03-21), so it isn’t comparable on the low-end scale.
Which companies closed in the most recent 90 days relative to the latest date shown?
The latest date in the list is 2026-06-18 (Portal, $9M). Within the following 90 days, the entries shown are Portal (2026-06-18, $9M) and Entact Bio (2026-06-03, $10M).
How concentrated are rounds in time—does the list cluster around particular years?
There’s a visible split between mid-2022 and late-2023/2024/2025: early in the timeline, multiple rounds land in 2022 (e.g., Affini-T Therapeutics $175M on 2022-03-22; EyePoint Pharmaceuticals $45M on 2022-03-09; Lyra Therapeutics $101M on 2022-04-08). Later years still show several large entries, including 2023-12 with Lyndra Therapeutics $101M (2023-12-21) and Seismic Therapeutic $121M (2023-12-04), and 2024 with Corner Therapeutics $54M (2024-04-18) plus Syncell $15M (2024-12-11).
What stage labeling dominates, and how much is missing or ambiguous?
“Series Unknown” appears 5 times across the 19 entries (e.g., Entact Bio $10M on 2026-06-03; EnPlusOne Biosciences $10M on 2025-02-19; Dynamic Cell Therapies $1M on 2024-07-11; Ingenia Therapeutics $5M on 2024-06-21; Selecta Biosciences $60M on 2023-11-13). There is also one additional non-numeric label for amount disclosure: Fluent BioSciences on 2024-03-21 shows “undisclosed,” while the rest use disclosed dollar amounts.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.